Arbutus to Receive $116 Million Strategic Investment from Roivant Sciences

Monday, 2 Oct 2017 

Oct 2 (Reuters) - Arbutus Biopharma Corp ::Signed share purchase agreement with Roivant Sciences for sale of convertible preferred shares for $116.4 million.Intends to use proceeds from sale to further develop, advance its clinical, preclinical HBV pipeline programs.Roivant will invest preferred shares which will be convertible into common shares at conversion price of $7.13/share.Roivant has agreed to a four year lock‐up period for the preferred shares investment and its existing holdings in co. 

Company Quote

-0.07 -4.58%
14 Jun 2019